While recent pharmaceutical innovations offer unprecedented possibilities for curing, treating, and preventing disease, stakeholders throughout the health care system have serious concerns about prescription drug affordability. Payment methods that incorporate concepts of value and patient-centered care are among the emerging policy options to address the cost of drugs for Medicare patients.
This briefing featured presentations by our experts highlighting the trends in Medicare regarding prescription drug pricing, and panelists discussed an array of policy options to align drug prices with value through alternative payment models.
Mark McClellan, Duke University
Gerard Anderson, Johns Hopkins Bloomberg School of Public Health
Laura Keohane, Vanderbilt University Department of Health Policy
Sarah Dash of the Alliance for Health Reform and Shawn Bishop of The Commonwealth Fund moderated the discussion.
Follow the briefing on Twitter: #MedicareRx
The Alliance for Health Reform gratefully acknowledges the support of The Commonwealth Fund for this event.
Full Transcript (Adobe Acrobat PDF)